EDNRB and neoplasm: Furthermore, the ETBR antagonist repressed VEGF-C/VEGFR-3 axis activation and prevented tumour growth and VM formation, suggesting that ET-1/ETBR might provide an essential therapeutic target for melanoma treatment by VEGFR-3.